Other States May Soon Follow
FREDERICK, Md., April 21 /PRNewswire/ -- Maryland Medicaid has approved medical necessity product reimbursement for ActiPatch(TM) for kidney-compromised patients. BioElectronics Corporation, (Pink Sheets: BIEL), is the maker of ActiPatch, a revolutionary drug-free anti-inflammatory patch which accelerates healing.
Many commonly used pharmaceutical agents including aspirin, ibuprofen (Advil, Motrin, Nuprin) and Naproxen (Aleve, Anaprox, Naprosyn) with regular use and most especially long-term use, can have serious complications such as ulcers and bleeding from the gastrointestinal tract. These medications have been known to worsen cardiovascular conditions, increase high blood pressure, kidney disease and diabetes.
Andrew J. Whelan, CEO of BioElectronics Corporation, explains, "ActiPatch with its non-invasive, very efficient treatment for swelling and pain while accelerating recovery is the medicine of the future available today. We are actively pursuing additional reimbursement approvals nationally. ActiPatch is an important product that not only works without side-effects, it also has the potential to help keep medical costs down at a time when medical and insurance costs appear to be spiraling out of control," adds Whelan.
ActiPatch(TM) is a wafer thin patch with an embedded battery operated microchip that delivers weeks of continuous pulsed RF therapy for less than a dollar a day. The unique ActiPatch(TM) delivery system, using patented technology, provides a cost-effective, home use method to reduce soft tissue pain and swelling.
ActiPatch has regulatory clearance by the FDA for the treatment of edema following blepharoplasty.
For more information visit http://www.bioelectronicscorp.com or call 866-757-2284.
BioElectronics Corporation is the maker of the ActiPatch(TM). A
|SOURCE BioElectronics Corporation|
Copyright©2008 PR Newswire.
All rights reserved